Cayla Ford

Phase II study of CIMAvax EGF plus nivolumab in previously treated, immunotherapy-naïve advanced NSCLC

CIMAvax-EGF is a novel epidermal growth factor (EGF)-depleting therapy that induces the development of anti-EGF antibodies to clear free serum EGF from circulation. The primary objective of this single-arm phase II trial (NCT02955290) was to evaluate 12-month overall survival (OS...